Read Article proto.life: Scientists have created an organism that defies the rules of biology by using nonstandard amino acids. And you probably have some questions. Katia Tarasava, PhD, interviewed our...
Read More
Read Article Julianna LeMieux, PhD, Senior Science Writer at Genetic Engineering & Biotechnology News, interviewed our CEO Dan Mandell, PhD, and describes how non-standard amino acids (NSAAs) enable a new...
Read More
LISTEN TO THE PODCAST CEO Dan Mandell joined Kevin Folta on the Talking Biotech Podcast for an in-depth, technical conversation on the potential of protein therapeutics. In this episode Dan...
Read More
WATCH THE VIDEO GRO Biosciences CEO Dan Mandell explains how combining computation and automation enables smaller companies to innovate at a pace and scale formerly relegated to large biotechnology companies....
Read More
LISTEN TO THE PODCAST In the same way that written English is built around an alphabet of just 26 letters, all life on Earth is built around a standard set...
Read More
BOSTON, April 11, 2023 - GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics,...
Read More
Every year brings its own distinct changes. For the life sciences industry, 2022 was marked by challenges such as the ongoing influence of the pandemic, a turbulent economy and a...
Read More
LISTEN TO THE PODCAST In this episode, we sit down with scientist and entrepreneur Daniel J. Mandell, Ph.D. Daniel is the Chief Executive Officer, Co-Founder, and Director of GRO Biosciences,...
Read More
After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr. Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
- Nicole Paulk, an expert in gene therapy, joins GRObio’s Scientific Advisory Board (SAB) as It Advances its ProGlyTM Immunomodulation Chemistries into Gene Therapy - BOSTON, September 7, 2022 -...
Read More
